Patent classifications
C07C277/00
Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof
The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice. Cationic amphiphiles with mannose-mimicking shikimoyl head-groups described in the present invention are likely to find future applications in the field of genetic immunization.
Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof
The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice. Cationic amphiphiles with mannose-mimicking shikimoyl head-groups described in the present invention are likely to find future applications in the field of genetic immunization.
Polymorphic forms of perindopril (L)-arginine and process for the preparation thereof
The present invention relates to novel and stable polymorphic forms of Perindopril (L)-Arginine designated as Form γ and amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form γ with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.
Polymorphic forms of perindopril (L)-arginine and process for the preparation thereof
The present invention relates to novel and stable polymorphic forms of Perindopril (L)-Arginine designated as Form γ and amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form γ with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.
Metformin salts to treat Type2 diabetes
Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.
COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
Integrated synthesis of commodity chemicals from waste plastic
A process to extract carbon from hydrophobic waste comprises: combining the hydrophobic waste with an oxide of an active metal to form a storable, moisture-resistant feedstock for high-temperature processing; heating the feedstock in a furnace to yield an effluent gas entraining a carbide of the active metal; cooling the effluent gas entraining the carbide of the active metal; introducing nitrogen into the cooled effluent gas entraining the carbide of the active metal, to yield a cyanamide of the active metal and elemental carbon; and acidically hydrolyzing the cyanamide of the active metal to yield a cyanamide compound and a salt of the active metal.
Integrated synthesis of commodity chemicals from waste plastic
A process to extract carbon from hydrophobic waste comprises: combining the hydrophobic waste with an oxide of an active metal to form a storable, moisture-resistant feedstock for high-temperature processing; heating the feedstock in a furnace to yield an effluent gas entraining a carbide of the active metal; cooling the effluent gas entraining the carbide of the active metal; introducing nitrogen into the cooled effluent gas entraining the carbide of the active metal, to yield a cyanamide of the active metal and elemental carbon; and acidically hydrolyzing the cyanamide of the active metal to yield a cyanamide compound and a salt of the active metal.
Compositions, methods, and systems for the synthesis and use of imaging agents
The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
METHOD FOR PREPARING GUANIDINO ACETIC ACID
A modified method for preparing guanidino acetic acid (GAA) involves reacting cyanamide with an excess molar amount of glycine in an aqueous reaction mixture, in the presence of a base. The method avoids high molar amounts of base or acid for pH control, and maintains the reaction selectivity and product yields.